Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How do serotonergic psychedelics treat depression: The potential role of neuroplasticity
Hewa Artin, Sidney Zisook, Dhakshin Ramanathan
World Journal of Psychiatry (2021) Vol. 11, Iss. 6, pp. 201-214
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications
Alexandria Tartt, Madeline Mariani, René Hen, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 6, pp. 2689-2699
Open Access | Times Cited: 240
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Kwonmok Ko, Emma I Kopra, Anthony J. Cleare, et al.
Journal of Affective Disorders (2022) Vol. 322, pp. 194-204
Closed Access | Times Cited: 90
Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
David E. Olson
Biochemistry (2022) Vol. 61, Iss. 3, pp. 127-136
Open Access | Times Cited: 80
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1945-1976
Open Access | Times Cited: 55
Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents
Erika Plazas, Nicoletta Faraone
Biomedicines (2023) Vol. 11, Iss. 2, pp. 461-461
Open Access | Times Cited: 24
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
Neuroimaging in psychedelic drug development: past, present, and future
Matthew B. Wall, Rebecca Harding, Rayyan Zafar, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 9, pp. 3573-3580
Open Access | Times Cited: 17
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Hannah N. Saeger, David E. Olson
Journal of Neurochemistry (2021) Vol. 162, Iss. 1, pp. 109-127
Open Access | Times Cited: 34
The Hallucinogenic Serotonin2A Receptor Agonist, 2,5-Dimethoxy-4-Iodoamphetamine, Promotes cAMP Response Element Binding Protein-Dependent Gene Expression of Specific Plasticity-Associated Genes in the Rodent Neocortex
Lynette A. Desouza, Madhurima Benekareddy, Sashaina E. Fanibunda, et al.
Frontiers in Molecular Neuroscience (2021) Vol. 14
Open Access | Times Cited: 33
Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series
Hewa Artin, Sean Bentley, Eamonn Mehaffey, et al.
EClinicalMedicine (2022) Vol. 48, pp. 101439-101439
Open Access | Times Cited: 24
Art therapy and neuroscience: evidence, limits, and myths
Christianne E. Strang
Frontiers in Psychology (2024) Vol. 15
Open Access | Times Cited: 4
Mental disorder and its treatment as a transformative experience
Daniel Villiger
Phenomenology and the Cognitive Sciences (2025)
Open Access
Dynapenia is associated with a higher risk of depressive symptoms among older adults
Chih-Ching Chang, Yung Liao, Jiaren Chen, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access
Psychedelic interventions for major depressive disorder in the elderly: Exploring novel therapies, promise and potential
Ionuț Tudorancea, Gabriela Dumitriṭa Stanciu, Carla Torrent, et al.
Dialogues in Clinical Neuroscience (2025) Vol. 27, Iss. 1, pp. 98-111
Open Access
A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression
Alexander Pilozzi, Simmie L. Foster, David Mischoulon, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12513-12513
Open Access | Times Cited: 8
How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework
Manon van den Berg, Igor Magaraggia, Rudy Schreiber, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1853-1879
Open Access | Times Cited: 11
Screening key genes related to neuropathic pain-induced depression through an integrative bioinformatics analysis
Ling Li, Hong Su, Yang Yang, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 24, pp. 1348-1348
Open Access | Times Cited: 8
A Multidisciplinary Hypothesis about Serotonergic Psychedelics. Is it Possible that a Portion of Brain Serotonin Comes From the Gut?
Noémi Császár-Nagy, Petr Bob, István Bókkon
Journal of Integrative Neuroscience (2022) Vol. 21, Iss. 5
Open Access | Times Cited: 5
Could Psychedelics Treat Neuropathic Chronic Pain?
Martinez Sosa, Iliff Jonathan
Neurological Sciences and Neurosurgery (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 1
Systematic characterization of Lysergic Acid Diethylamide metabolites in Caenorhabditis elegans by ultra-high performance liquid chromatography coupled with high-resolution tandem mass spectrometry
Christiane Martins de Vasconcellos Silveira, Vanessa Farelo dos Santos, Isis M. Ornelas, et al.
Journal of Chromatography A (2023) Vol. 1708, pp. 464362-464362
Closed Access | Times Cited: 1
Einstellungen zur Einführung der psychedelischen Therapie
Nina Hartter, Marvin Däumichen, Andrea Jungaberle, et al.
Nervenheilkunde (2024) Vol. 43, Iss. 06, pp. 357-365
Closed Access
The promise of psychedelic research
Carina Peritore
Future Drug Discovery (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 2
Neuroimaging in psychedelic drug development: Past, present, and future
Matthew B. Wall, Rebecca Harding, Rayyan Zafar, et al.
(2022)
Open Access | Times Cited: 2
Systematic Characterization of LSD metabolites inC. elegansby ultra-high performance liquid chromatography coupled with high-resolution tandem mass spectrometry
Christiane Martins de Vasconcellos Silveira, Vanessa Farelo dos Santos, Isis M. Ornelas, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Evidencias y perspectivas del potencial antidepresivo del “alcaloide mágico” psilocibina: una revisión narrativa
María Marcela Velásquez Toledo
Cultura y Droga (2023) Vol. 28, Iss. 35, pp. 91-113
Open Access
Page 1 - Next Page

Scroll to top